

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

June 9, 2022

To: Shareholders

Company name Renascience Inc.
Name of Representative: Koji Naito, President & CEO
(Security Code: 4889 Tokyo Stock Exchange Growth)
Inquiries to: Kazuhiro Ikeda, Director, CFO

Notice of Conclusion of Memorandum of Understanding with Daiichi Sankyo Company, Limited to Amend Agreement Concerning Preferential Negotiation Rights with Option Rights

The Company hereby announces that the Company has agreed to execute a Memorandum of Amendment to the Agreement Concerning Preferential Negotiating Rights with Option Right dated on December 25, 2020 with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") (collectively, the "Agreement") to further extend the option period of the Memorandum of Amendment dated October 26, 2021 to extend the term of the Agreement to December 31, 2022.

Under the terms of the agreement, The Company grants Daiichi Sankyo the option and priority negotiation rights to develop and commercialize RS5614, a plasminogen activator inhibitor-1 inhibitor (the "Drug Candidate"), for the treatment of lung diseases including novel coronavirus pneumonia and other lung injuries for the period ending June 30, 2022, with the possibility of further extension of the period upon mutual discussion.

At the time of execution of the Agreement, the late Phase II investigator-initiated clinical trial (the "Trial") for this Drug Candidate was scheduled to be completed in March 2022, and the option period for this trial was set at June 30, 2022. However, the Company had extended the Trial period.

Based on the above circumstances, Daiichi Sankyo requested an extension of the option period taking into consideration the timing of the completion of the Trial currently underway.

There is no particular impact on the earnings forecast for the fiscal year ending March 31, 2023 at this time.

End